Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ajay Kalra

Vascular Surgery Fort Myers, FL Medical Doctor

NPI 1942294343 CMS profile 223858

6821 Palisades Park Ct, Fort Myers, FL 33912

Open in the dashboard

General payments

$69,957

794 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ajay Kalra of Fort Myers, FL is reported in the CMS Open Payments database as having received $69,957 across 794 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $13,252 84
2024 General $8,806 110
2023 General $10,586 133
2022 General $12,643 133
2021 General $9,816 124
2020 General $6,257 95
2019 General $8,597 115

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ajay Kalra
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Ajay Kalra were reported at $13,252. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Ajay Kalra Vascular Surgery median Middle half National median
2019 $8,597 $796 $226–$2,363 $163
2020 $6,257 $348 $118–$1,110 $114
2021 $9,816 $471 $158–$1,421 $132
2022 $12,643 $725 $222–$2,183 $149
2023 $10,586 $836 $257–$2,440 $160
2024 $8,806 $909 $252–$2,619 $164
2025 $13,252 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $14,144 148 payments
  2. Boston Scientific Corporation $11,180 61 payments
  3. W. L. Gore & Associates, Inc. $7,796 83 payments
  4. Penumbra, Inc. $7,082 86 payments
  5. Cook Medical LLC $6,316 73 payments
  6. Silk Road Medical, Inc. $5,540 50 payments
  7. Endologix, Inc. $4,312 23 payments
  8. Bard Peripheral Vascular, Inc. $2,009 24 payments
  9. Medtronic Vascular, Inc. $1,889 43 payments
  10. Aroa Biosurgery Incorporated $794 5 payments
  11. Other $8,895 198 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $57,224 777 payments
  2. Travel and Lodging $7,233 14 payments
  3. Consulting Fee $5,500 3 payments
Products named General payments · program years 2019–2025
  1. ENDURANT IIS $11,595 113 payments
  2. General - Therapies $6,359 10 payments
  3. Indigo System $4,183 47 payments
  4. ENROUTE Transcarotid Stent $3,463 35 payments
  5. ENROUTE Transcarotid Neuroprotection System $3,463 35 payments
  6. Zilver PTX $3,455 34 payments
  7. AFX2 Bifurcated Endograft System $2,747 12 payments
  8. EXCLUDER Conformable AAA Endoprosthesis with Active Control $2,522 24 payments
  9. ENROUTE 0.014 Guidewire $2,077 15 payments
  10. ENROUTE Transcarotid Stent System $2,077 15 payments
  11. Other $41,134 599 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

593

Median for Vascular Surgery: 122

Drug cost

$69,795

Median for Vascular Surgery: $14,135

Branded share of claims

88.7%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 42 $47,167
Brilinta Ticagrelor Brand 18 $17,859
Clopidogrel Clopidogrel Bisulfate Brand 385 $4,416
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 81 $240
Diazepam Generic 51 $65
Prednisone Generic 16 $50

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 98 billing codes

Paid by Medicare

$631,314

Of which drugs: $662

Medicare patients

506

Average age 76

Services billed

7,868

209 women, 297 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 64%
Arthritis 63%
Chronic kidney disease 57%
Diabetes 47%
Heart failure 39%
Atrial fibrillation 39%
COPD 35%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 82 6,174 $648

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

794 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record